Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
When do you consider disease modifying therapy in radiographically isolated syndrome?
Does reclassification of RIS as MS in upcoming McDonald Criteria change this decision for you?
Related Questions
When do you consider pembrolizumab for the treatment of progressive multifocal leukoencephalopathy?
How does your decision to use high-efficacy disease-modifying treatments (HET) differ, if at all, when treating late-onset relapsing-remitting multiple sclerosis?
When do you switch to a different DMT in multiple sclerosis patients planning for pregnancy?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
When should patients be referred for advanced MRI testing to assess for CVS and PRL?
What are red flags in an evaluation for possible multiple sclerosis that should prompt workup for genetic/inherited conditions?
How do you counsel women on anti-CD20 therapy for MS who are planning for pregnancy?
What therapy do you recommend in situations where IV steroids and IVIg do not help patients with GABA-A encephalitis?
At what degree of lymphopenia do you switch/discontinue dimethyl fumarate in patients with multiple sclerosis?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?